CLPT ClearPoint Neuro, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1285550 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY32.5%
TTM net income YoY-56.2%
TTM EPS YoY-45.8%
Revenue 3-yr CAGR26.8%
Net income 3-yr CAGR—
Margins
Gross margin61.4%
Operating margin-70.6%
Net margin-79.4%
FCF margin-106.0%
EBITDA margin-69.3%
Returns
ROE-167.5%
ROA-41.8%
ROIC (approx.)-130.8%
Asset turnover0.53x
Leverage & solvency
Liabilities / assets75.8%
Debt / equity1.86x
Current ratio6.76x
Interest coverage-6.03x
Cash quality & payout
Operating cash flow / net income1.31x
Accruals ratio12.7%
Payout ratio—
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.07M | $10.88M | $12.13M | $10.41M | $8.86M | $9.21M | $8.48M | $7.77M |
| Cost of revenue | $5.02M | $4.17M | $4.37M | $4.01M | $3.26M | $3.66M | $3.35M | $3.01M |
| Gross profit | $7.06M | $6.71M | $7.76M | $6.40M | $5.60M | $5.56M | $5.13M | $4.76M |
| R&D expense | $4.02M | $4.63M | $4.52M | $3.24M | $3.45M | $3.83M | $3.38M | $3.33M |
| SG&A expense | $3.84M | $5.55M | $5.00M | $5.44M | $3.59M | $3.39M | $4.08M | $3.26M |
| Operating income | -$6.33M | -$10.24M | -$8.48M | -$7.04M | -$5.28M | -$5.68M | -$6.16M | -$5.64M |
| Interest expense | $1.45M | $1.41M | $1.38M | $1.08M | $939,000 | $365,000 | $0 | — |
| Pretax income | -$7.46M | -$11.38M | -$9.54M | -$7.78M | -$5.88M | -$5.81M | -$6.01M | -$5.42M |
| Income tax | -$4,000 | -$38,000 | $8,000 | $4,000 | $8,000 | $25,000 | $18,000 | -$32,000 |
| Net income | -$7.46M | -$11.34M | -$9.55M | -$7.79M | -$5.89M | -$5.84M | -$6.03M | -$5.39M |
| EBITDA | -$6.23M | -$10.09M | -$8.39M | -$6.80M | -$5.21M | -$5.28M | -$6.06M | -$5.40M |
| EPS (basic) | -0.24 | -0.38 | -0.32 | — | -0.21 | -0.21 | -0.22 | — |
| EPS (diluted) | -0.24 | -0.38 | -0.32 | — | -0.21 | -0.21 | -0.22 | — |
| Weighted avg. shares (diluted) | 30.98M | 30.17M | 29.55M | — | 28.43M | 28.26M | 27.72M | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | -$543,000 | -$80,000 | $151,000 | $226,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $46.18M | $29.36M | $35.59M | $45.92M | $38.22M | $41.54M | $12.39M | $20.10M |
| Receivables | $8.02M | $8.39M | $8.66M | $6.55M | $4.00M | $4.26M | $3.65M | $4.71M |
| Inventory | $9.77M | $8.81M | $8.57M | $8.36M | $6.58M | $6.29M | $6.58M | $6.86M |
| Current assets | $66.71M | $48.93M | $54.88M | $63.60M | $51.33M | $53.99M | $24.21M | $33.36M |
| PP&E, net | $3.12M | $2.99M | $2.91M | $2.62M | $2.11M | $2.02M | $2.18M | $2.00M |
| Goodwill | $7.47M | $7.47M | $7.47M | $7.47M | — | — | — | $7.47M |
| Intangibles | $12.41M | $12.91M | $13.42M | $13.92M | — | — | — | $0 |
| Total assets | $112.73M | $86.74M | $93.42M | $97.75M | $60.36M | $62.87M | $30.07M | $39.19M |
| Current liabilities | $9.87M | $10.31M | $9.48M | $10.77M | $8.05M | $7.40M | $6.87M | $10.35M |
| Long-term debt | $50.84M | $50.23M | $49.64M | $49.08M | $29.20M | $28.84M | — | — |
| Total debt | $50.84M | $50.23M | $49.64M | $49.08M | $29.20M | $28.84M | — | — |
| Total liabilities | $85.46M | $75.97M | $74.58M | $69.73M | $44.48M | $43.13M | $10.08M | $13.80M |
| Shareholders' equity | $27.27M | $10.78M | $18.84M | $28.02M | $15.87M | $19.74M | $19.99M | $25.39M |
| Net debt | $4.66M | $20.87M | $14.05M | $3.15M | -$9.02M | -$12.70M | — | — |
| Shares outstanding | 32.05M | 30.50M | 29.99M | 29.37M | 28.43M | 28.42M | 27.98M | 27.62M |
| Cash flow statement | ||||||||
| Operating cash flow | -$20.10M | -$7.01M | -$7.97M | -$12.08M | -$3.12M | -$2.55M | -$6.17M | -$1.24M |
| Capital expenditure | $137,000 | $214,000 | $645,000 | $49,000 | $199,000 | $91,000 | $183,000 | $263,000 |
| Free cash flow | -$20.24M | -$7.23M | -$8.61M | -$12.13M | -$3.32M | -$2.64M | -$6.36M | -$1.51M |
| Investing cash flow | -$137,000 | -$214,000 | -$645,000 | $1.09M | -$199,000 | -$91,000 | -$183,000 | -$263,000 |
| Financing cash flow | $22.07M | $1.00M | -$1.84M | $19.56M | $0 | $31.98M | -$1.36M | $37,000 |
| Depreciation & amortization | $103,000 | $150,000 | $86,000 | $249,000 | $66,000 | $396,000 | $103,000 | $240,000 |
| Stock-based compensation | $1.88M | $2.27M | $2.22M | $1.98M | $2.02M | $2.27M | $1.91M | $1.70M |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.